A discovery of a biomarker in non small cell lung cancer (NSCLC)is usually met with relief.
However, oncologists treating patients whose genetic analysis comes back with a HER2 marker feel anything but.
For decades patients have faced all the burden with no TKI in sight.
This lag in treatment innovation has gone on for far too long.
It’s time to end the wait.